No abstract

Background: Middle Eastern women worldwide increasingly seek aesthetic treatment to enhance their beauty and improve self-esteem, but literature describing standards of beauty across the Middle East are scarce. Knowledge of facial anthropometry and Middle Eastern subregional beauty preferences and aesthetic weaknesses are key to develop an effective facial enhancement strategy that does not jeopardize ethnic identity or facial harmony. Methods: Dermatologists and plastic surgeons from 8 Middle Eastern countries who had 7.5–25 (mean 13.5) years of experience in aesthetic medicine examined female Middle Eastern beauty in 4 geographic subregions: the Gulf (comprising Bahrain, Kuwait, Saudi Arabia, and the United Arab Emirates), Iran, Lebanon, and Egypt. They developed consensus opinions regarding facial beauty, aesthetic deficiencies, and injectable treatment solutions. Results: Facial anthropometry differs between Middle Eastern and Western women, and also within the region. Although subregional differences are seen, beauty is generally recognized by an oval or round face; temple fullness; pronounced, elevated, arched eyebrows; large almond-shaped eyes; well-defined, laterally full cheeks; a small, straight nose; full lips; a well-defined jawline; and a prominent, pointed chin. The relative prominence of the nose necessitates attention to the lips and the shape and projection of the chin. Aging is often accompanied by midface sagging that leads to increased heaviness in the lower facial third. Conclusions: Middle Eastern beauty is characterized by striking eyes, defined cheeks, and full lips. These consensus opinions inform aesthetic practitioners who treat Middle Eastern women worldwide about their aesthetic ideals and the implications for treatment.

No abstract

Although pigmentation in our patients was lower than previous reports from Iran and other countries, however, we signified adding excimer to MKT increased the pigmentation rate in treated patches. Further investigations are recommended with longer follow-up and larger series to validate the findings reported here.

Psoriasis is known to be associated with increased risk of cardiovascular diseases. High‐sensitivity C‐reactive protein (hs‐CRP) is a marker of inflammation and an independent risk factor for atherosclerosis. We aimed to assess the correlation between hs‐CRP and subclinical atherosclerosis in psoriatic patients. In 60 patients with moderate to severe psoriasis and 60 age‐ and gender matched healthy controls, we evaluated the serum hs‐CRP level and mean intima‐media thickness of the common carotid artery (MIMT‐CCA). Psoriatic patients had higher levels of hs‐CRP (median, 2.25 mg/L; IQR, 0.98‐3.80; and range, 0.29‐11.60) than did those in the control group (median, 1.03 mg/L; IQR, 0.36‐2.15; and range, 0.10‐3.35). Psoriatic patients also had higher mean MIMT (0.74 ± 0.19 and 0.54 ± 0.12, respectively, and P < .0001) compared with healthy subjects. The serum level of hs‐CRP was significantly correlated with MIMT (P < .0001). Our results indicate that psoriatic patients have a higher risk of subclinical atherosclerosis and hs‐CRP may be a useful marker for future risk of cardiovascular diseases in these patients. So, not only does anti‐inflammatory drugs play a key role in the treatment of psoriasis, but also they may reduce the risk of cardiovascular diseases by decreasing level of inflammatory markers including hs‐CRP.

Injection of botulinum toxin type A through the temporal hairline to correct supraciliary wrinkles seems to be safe and effective.

No abstract

upon hospitalization. Therefore maximum cautious must be considered to prevent such a risk. It is mandatory to treat patients in a unit specified to with COVID-19 negative patients. Exacerbation of lesions secondary to administration of rituximab has been reported but COVID-19 positivity is highly suspected in this patient. 7 We replaced her treatment protocol with IVIg, as in cases of pemphigus vulgaris associated with COVID-19 infection IVIg is the treatment of choice. 4-6 Our patient was controlled with this treatment. Further investigations are needed to evaluate the most appropriate treatment schedule for pemphigus vulgaris in the COVID-19 pandemic.